Dynavax Technologies

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative therapeutic products to treat and prevent infectious diseases, allergies, and cancer. Our versatile, proprietary approaches alter specific immune responses by activating a unique receptor called Toll-Like Receptor 9 (TLR9) found on certain immune system cells. To target TLR9, we are using immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our clinical development pipeline includes: HEPLISAV™, a hepatitis B vaccine in Phase 3 clinical trials; TOLAMBA™, a ragweed allergy immunotherapeutic; a hepatitis B therapy in a Phase 1 trial; and a cancer therapy for non-Hodgkin's lymphoma (NHL) in a Phase 2 trial and for metastatic colorectal cancer in a Phase 1 trial. Our preclinical program in asthma and chronic obstructive pulmonary disease (COPD) is partnered with AstraZeneca. Our preclinical work on an influenza vaccine is funded in part by the National Institutes of Health (NIH), while our colorectal cancer clinical trial and preclinical hepatitis C therapeutic program are funded by Symphony Dynamo, Inc. While the NIH and Symphony provide program support, Dynavax has retained rights to seek strategic partners for future development and commercialization.

Contact Details: 2929 Seventh Street, Suite 100 Berkeley CA 94710 United States of America Tel: +1.510.848.5100 Fax: +1.510.848.1327 Email: contact@dynavax.com WWW: www.dynavax.com/

Loading...

Recent Publications by Dynavax Technologies:
Development of TLR inhibitors for the treatment of autoimmune diseases. SUMMARY: The innate immune system is a critical element of protection from...	11th July, 2008	Dynavax Technologies Corporation, Berkeley, CA 94710, USA.	Immunol Rev. 2008 Jun;223:271-83. DOI Direct Link
Separation of N-glycans by HPLC. Most glycoproteins carry a very heterogeneous mixture of oligosaccharides...	5th June, 2008	Dynavax Technologies, Berkeley, CA, USA.	Methods Mol Biol. 2008;446:239-54. DOI Direct Link
PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. Plasmacytoid predendritic cells (pDCs) are the main producers of type I...	18th March, 2008	Dynavax Technologies Corporation, Berkeley, CA 94710, USA.	J Exp Med. 2008 Feb 18;205(2):315-22. Epub 2008 Jan 28. DOI Direct Link
Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. The presence of autoantibodies specific for nucleic acid-associated...	29th February, 2008	Dynavax Technologies Corporation, Berkeley, CA 94710, USA.	Eur J Immunol. 2007 Dec;37(12):3582-6. DOI Direct Link
Immunostimulatory DNA as a vaccine adjuvant. Immunostimulatory DNA containing unmethylated CpG motifs is recognized by...	6th December, 2007	Preclinical Research, Dynavax Technologies, 2929 Seventh Street, Suite	Expert Rev Vaccines. 2007 Oct;6(5):747-59. DOI Direct Link
→View more Dynavax Technologies research publications.

BioNews Results for Dynavax Technologies:
Dynavax and Mercks Hepatitis B Vaccine Trial Meets Primary Goal	FDA News:  Aug 12 2008 10:13PM Matching: dynavax technologies
Dynavax and Merck’s Hepatitis B Vaccine Trial Meets Primary Goal	FDA News:  Aug 12 2008 9:49PM Matching: dynavax technologies
Phase III trial of HBV vaccine meets primary endpoint	Bio Spectrum Asia:  Aug 11 2008 8:23AM Matching: dynavax technologies
Dynavax, Merck's phase-3 trial with hepatitis B vaccine meet endpoint	PharmaBiz:  Aug 9 2008 5:53AM Matching: dynavax technologies
Shares of Dynavax Technologies Corporation (NASDAQ: DVAX) Climb on Successful Phase 3 Trial and Second Quarter	TransWorldNews:  Aug 8 2008 3:49PM Matching: dynavax technologies
Promote your company here: BioNewsCast - Press Release Distribution	→View more Dynavax Technologies news.

Dynavax Technologies Patents:
US Patent No.	Title
7255868	Chimeric immunomodulatory compounds and methods of using the same--I
7250403	Biodegradable immunomodulatory formulations and methods for use thereof
7223398	Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
7183111	Immunomodulatory formulations and methods for use thereof
7157437	Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
→View more Dynavax Technologies patents.

Dynavax Technologies (DVAX) Financial information Links from Barchart
DVAX Quote from from Barchart.com
DVAX Chart from from Barchart.com
DVAX Profile from from Barchart.com
DVAX Opinion from from Barchart.com
→View more Dynavax Technologies finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 237 times since April 2007, the link to the organisation's website has been followed 47 times

Recent Search Terms used to find this page: Dynavax Technologies | barchart dynamo | Expert Rev Vaccines. 2007 Oct65747-59 | Dynavax influenza | .

Search for more companies in Berkeley

Search for more companies in CA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Dynavax Technologies